 SAN FRANCISCO, March 16, 2021 PRNewswire -- Kindred Biosciences, Inc. NASDAQ: KIN, a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided updates on its programs. For the fourth quarter of 2020, KindredBio reported net revenues of 1.0 million and a net loss of 10.9 million, or 0.28 per share. 